BioInItaly Newsletter

La vetrina del biotech italiano all’estero
  • 25 gen, 2017
    Sommario
    Axxam SpA is a member of the PHAGO Consortium
    Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand 
    Newron Pharmaceuticals S.p.A., preliminary results of the use of Evenamide in patients with schizophrenia
    Kedrion Biopharma strengthens its presence in Russia
    The European Medicines Agency has validated the submission of Conditional Marketing Authorisation for NGR-hTNF 
    Bio-on announces new multi-license maxi agreement for revolutionary phas bioplastic 
  • 16 dic, 2016
    Sommario
    Sofinnova Partners announces the successful sale of Creabilis to Sienna Biopharmaceuticals for a total consideration of $150 M
    Advanced Accelerator Applications Announces European Commission Approval of SomaKit TOC™
    European Commission Grants Intercept's Ocaliva® (obeticholic acid) Marketing Authorization for the Treatment of Primary Biliary Cholangitis
    Axxam executes a transaction with Acousia Therapeutics GmbH
    MolMed coordinates a CAR T-cell immunotherapy project awarded a 5.9 million Euro grant by the European Commission 
    Neurotrophic keratitis: EMA validates the marketing authorisation application for cenegermin eye drops (Oxervate®) submitted by Dompé
    Chugai and Berlin-Chemie - the Menarini Group Announce Global License Agreement for an Anti-cancer Agent, PA799
  • 25 nov, 2016
    Sommario
    Chiesi enhances asthma portfolio with acquisition of Atopix Therapeutics
    KYMOS acquires Italian firm Pharmaprogress
    DiaSorin launches its first molecular test with the new business division, DiaSorin Molecular
    Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC
    BIO-ON and ITALERI present results of research and development of Minerv PHA Supertoys Bioplastic in Germany in 2017 
    Mater-Biotech: inaugurated the world first plant for the production of bio-butanediol from renewable resources
  • 04 ott, 2016
    Sommario
    Axxam and Mercachem Sign a Strategic Alliance for Integrated Drug Discovery Services
    Molmed:  the European Commission grants a Conditional Marketing Authorisation to Zalmoxis®, the first immunogene therapy for the treatment of adult patients with high-risk haematological malignancies
    Genenta Science, Amgen, Ospedale San Raffaele deal
    Bio-on: nanotechnologies and bioplastic to diagnose and combat tumours
  • 25 lug, 2016
    Sommario
    Zambon lauches Xadago® (safinamide) in the Netherlands for patients with mid-to-late-stage Parkinson’s Disease
    MolMed receives positive COMP opinion on the orphan drug designation for Zalmoxis®
    Advanced Accelerator Applications Announces FDA Priority Review for Lutathera
    Kedrion Biopharma consolidates presence on Russian Market
  • 17 giu, 2016
    Sommario
    Advanced Accelerator Applications Expands U.S. NETSPOT™ Supply Chain with Two Additional Radiopharmacy Networks
    The European Commission grants the European marketing authorisation to StrimvelisTM, GSK’s stem cell therapy for ADA-SCID patients
    FDA Grants Accelerated Approval to Ocaliva™ (Obeticholic Acid) for the Treatment of Patients with PBC
    Nouscom concludes successful series A financing of EUR 12 million
  • 25 mag, 2016
    Sommario
    Zambon launches XADAGO® (Safinamide) in the U.K. for patients with mid- to late-stage Parkinson’s Disease 
    Advanced Accelerator Applications preparing for Lutathera launch by scaling up production in Ivrea, Italy – Company provides update on key European production site
    Axxam expands to U.S., opens office in Cambridge, Mass.
    Revolution in food packaging. The milk carton goes bio 
  • 12 apr, 2016
    Sommario
    Ongoing Phase II Study of Evenamide (NW-3509) May Suggest an Alternative Approach to the Treatment of Schizophrenia
    GSK receives positive CHMP opinion in Europe for Strimvelis™, the first gene therapy to treat very rare disease, ADA-SCID 
    Diasorin Shopping in USA
    MolMed and Genenta Science sign a collaboration agreement in the field of gene therapy for the treatment of tumors 
    Menarini announces the founding of Vaxynethic, joint venture with Biosynth
  • 08 mar, 2016
    Sommario
    World’s first material formulations laboratory to make MINERV PHAs advanced bioplastic 
    Drug Discovery Collaboration between Grünenthal and Axxam
    Zambon Launches Xadago® (Safinamide) In Italy For Patients With  Mid- To Late-Stage Parkinson’s Disease 
    Axxam and the NEOMED Institute to Collaborate on the Discovery and Development of a Novel Drug to Treat Metabolic Diseases 
  • 09 feb, 2016
    Sommario
    Kedrion Biopharma strengthens its position on the US Market
    AbbVie invests in Italy: 60 million dollars in arrival to the manufacturing site
    Zambon launches Xadago® (Safinamide) in Switzerland for patients with parkinson’s disease
    BioInItaly Investment Forum 2016, where biotech meets investors. 19-20 April in Milan
  • 08 gen, 2016
    Sommario

    The European Commission grants Orphan Drug Designation to Sirolimus (Rapamycin) for the treatment of beta thalassaemia intermedia and major
    Science Translational Medicine published results of a study highlighting the role of memory stem T cells in the treatment of leukaemia
    Axxam and the Neurodegeneration Consortium at The University of Texas MD Anderson Cancer Center collaborate on a novel approach to Alzheimer’s disease research
    EryDel Consortium Gains € 6 million of EU Funding for Development of EDS  for the treatment of Ataxia Telangiectasia
    Capital Increase of  Flowmetric Europe
    Bioplastic created for the toys of the future safe and eco-sustainable, child-friendly and environmentally sound

  • 03 dic, 2015
    Sommario
    MolMed: AIFA granted authorization to manufacture gene therapies for marketing purposes
    Newron Completes 5.4 Million USD/CHF Private Placement with U.S. Biotechnology/Healthcare Specialist Fund
    Advanced Accelerator Applications S.A. listed on the US Nasdaq stock Exchange
    Newron initiates U.S. Phase II trial in patients with schizophrenia